Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 153

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 147 148 149 150 151 152 < 153 > 154 155 156 157 158 159 .. 184 >> Следующая

30. Насонов ЕЛ, Иванова ММ. Антималярийные (аминохинолиновые) препараты: новые фармакологические свойства и перспективы клинического применения Клин. фарма-кол. терапия, 1998; 3: 65—68.
31. Yoon KH. Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndrome. J Rheumatol 2002; 29: 1574—1575.
32. Costedoat-Chalumeau N, Amoura Z, Du-haut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. A study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48: 3207—3211.
33. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first throm-botic event in 70patients. Ann Intern Med 1992; 117: 303—308.
34. Krnic-Barrie S, O'Connor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101—2108.
35. Meroni PL, Moia M, Derksen RHWM, et al. Venous thromboembolism in the antiphospho-lipid syndrome: management guidelines for second prophylaxis. Lupus 2003; 12: 504—507.
36. Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003; 12: 508—513.
37. Valentini KA, Hull RD. Clinical use of warfarin. UpToDate 2003; 12.1.
38. Hirsh J, Poller L. The International Normalisation Ratio: a guide to understanding and correcting its problems. Arch Intern Med 1994; 154: 282.
39. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy. Circulation 2003; 107; 1692—1711.
40. Jillella AP, Lutcher CL. Reinstitution warfarin in patients who develop warfarin skin necrosis. Am J Hematol 1996; 52: 117—119.
41. Buller HR, Prins MH. Secondary prophylaxis with warfarin for venous thromboembolism. New Engl JMed 2003; 349: 702—704.
42. Van Dongen CJJ, Vink R, Hutten BA Buller HR, Prins MH. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first events. A meta-analysis. Arch Intern Med 2003; 163: 1285—1293.
43. Shulman S. Care of patients receiving long-term anticoagulant therapy. New Engl J Med 2003; 349: 675—683.
44. Van der Meer FJM, Rosendaal FR, Van-denbroucke JP, Briet E. Bleeding complications in oral anticoagulant patients. Arch Intern Med 1993; 153: 1556—1562.
45. Fitzmaurici DA, Blann AD. Lip GYH. Bleeding risk of anticoagulant therapy. BJM 2002; 325: 828—831.
46. Gullov AL, Koefoed BG, Peterson P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulant. Arch Intern Med 1999; 159: 1322—1328.
47. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657.
48. River G, Khamashta MA, Hughes GRV. Warfarin and azathioprin: a drug interaction does exist. Am J Med 1993; 95: 342.
49. Costedoat-Chalumeau N, Amoura Z, et al. Potentiation of vitamin K antagonist by high dose intravenous methylprednisolone. Ann Intern Med 2000; 132: 831—635.
50. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphism in the cytochrome P450CY2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717—719.
51. Gorter JW. Major bleeding during anticoag-ulation after cerebral ischemia: patterns and risk factors. Neurology 1999; 53: 1319—1327.
52. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among
SHS-OOO4.qxd 21.11.2006 16:56 Page 374
7B-
Насонов Е.Л. Антифосфолипидный синдром.
patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104:332.
53. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685.
54. Prandoni P, Simioni P, Girolami A. Anti-phospholipid antibodies, recurrent thromboem-bolism, and intensity of warfarin anticoagulation. Thromb Haemost 1996; 75: 859.
55. Rance A, Ememrich J, Fiessinger JH. Anti-cardiolipin antibodies and recurrent thromboem-bolism. Thromb Haemost 1997; 77: 221—222.
56. Ruiz-Irastorza G, Khamashta MA, Caetel-lino G, Hughes GRV. Systemic lupus erythemato-sus. Lancet 2001; 357: 1027—1032.
57. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New Engl J Med 2003; 349: 1133—1138.
58. Ridker RM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboem-bolism. New Engl J Med 2003; 348:1425—1434.
59. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous throm-boembolism. New Engl J Med 2003; 349: 631— 639.
Предыдущая << 1 .. 147 148 149 150 151 152 < 153 > 154 155 156 157 158 159 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed